At a glance
What is it—and why does it matter?
Retatrutide is a novel triple agonist that targets the glucagon receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon-like peptide-1 receptor. Retatrutide activates GLP-1R, GIPR, and the glucagon receptor. The main outcome was HbA1c change at 24 weeks; secondary outcomes included HbA1c and weight change at 36 weeks. Serious allergic reactions, including anaphylaxis, have been reported.
Sources for this introduction: [1] [2] [3] [4]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
Simple guide
Retatrutide, in plain English
The main points from the published research. Each one links to the source it comes from.
What it is
Retatrutide is listed as a protein.
Source for this finding
“Molecule type: Protein”
RETATRUTIDE
What the research looks like
Most published findings come from studies in people.
- 39 People 49%
- 11 Animals or lab 14%
- 29 Other or unclear 37%
Counts show where findings come from, not how strong they are. Animal and lab findings are counted together because study types have not been labelled for this profile yet.
What studies in people found
Retatrutide showed the largest weight reduction versus placebo among the agents listed.
Source for this finding
“Retatrutide demonstrated the greatest weight reduction versus placebo (MD -13.44 kg; 95% CI [-18.38, -8.51]), followed by survodutide (MD -10.74 kg; 95% CI [-15.68, -5.80]) and mazdutide (MD -6.47 kg; 95% CI [-10.71, -2.24]). Cotadutide showed the smallest and nonsignificant effect (MD -3.41 kg; 95% CI [-11.63, 4.81]).”
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.In the included trials, 510 participants received retatrutide and 130 received placebo.
Source for this finding
“Retatrutide was administered to 510 participants, while 130 received a placebo.”
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.This was a phase 2 randomized, double-blind trial comparing retatrutide with placebo and an active comparator in the USA.
Source for this finding
“In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.”
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.The review analyzed trials comparing dual or triple GLP-1-based polyagonists to placebo in adults with MASLD or MASH; retatrutide was among the polyagonists.
Source for this finding
“This systematic review and meta-analysis evaluated randomized controlled trials comparing dual or triple GLP-1-based polyagonists with placebo in adults with MASLD or MASH.”
Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.At 36 weeks, retatrutide at 4 mg or higher led to significantly more weight loss than placebo and dulaglutide.
Source for this finding
“For retatrutide doses of 4 mg and greater, decreases in weight were significantly greater than with placebo (p=0·0017 for the 4 mg escalation group and p<0·0001 for others) and 1·5 mg dulaglutide (all p<0·0001).”
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
What animal and lab studies suggest
Not proven in people. Results in animals or cells often do not hold up in humans.
In diabetic rats, Retatrutide lowered blood glucose but did not stop weight loss.
Source for this finding
“Retatrutide reduced blood glucose levels but did not prevent diabetes-associated weight loss.”
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.Retatrutide was tested for anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis in HK-2 cells and mouse UUO and aging models.
Source for this finding
“we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models.”
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.Retatrutide did not stop the diabetes-related weight loss.
Source for this finding
“but did not prevent diabetes-associated weight loss.”
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Safety
Do not use retatrutide if you have a history of recurrent or severe hypoglycemia.
Source for this finding
“Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia.”
dailymed-lead-42498bee“Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia.”
dailymed-lead-425d04f6Do not use retatrutide if you are pregnant or breastfeeding.
Source for this finding
“Pregnancy and breastfeeding: Do not use if pregnant or breastfeeding.”
dailymed-lead-42498beeUsing it with insulin or sulfonylureas may increase hypoglycemia risk.
Source for this finding
“Using it with insulin or sulfonylureas may increase the risk of hypoglycemia.”
dailymed-lead-42498bee
How it's used
These describe specific products as labelled or studied. They are not dosing instructions.
From week 13 and beyond: 0.75 mL (10 mg) once weekly.
Source for this finding
“Week 13 and beyond 0.75 mL (10 mg) once weekly”
dailymed-lead-42498beeEach kit has Retatrutide 10 mg (lyophilized powder) and Sterile Water for Injection 1 mL.
Source for this finding
“Retatrutide 10 mg (lyophilized powder)Sterile Water for Injection 1 mL”
dailymed-lead-425d04f6
What we don't know
- Not yet covered in this profile: administration, regulatory status.
A missing finding does not mean something is safe or effective.
See all 84 findings and sourcesEvery finding, grouped by topic, with its exact source passages
What is it?
A molecule, not a product name.
Identity
Retatrutide is listed as a protein.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Molecule type: Protein”
RETATRUTIDE · Molecule identity
Identity
Retatrutide is named as a newer GLP-1 receptor agonist-based obesity medication in this Review.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This Review synthesises evidence from randomised controlled trials and high-quality meta-analyses on approved and late-stage investigational obesity medications, including phentermine-topiramate, naltrexone-bupropion, glucagon-like peptide-1 (GLP-1) receptor agonists (eg, liraglutide, semaglutide, subcutaneously and orally), and newer GLP-1 receptor agonist-based agents (eg, tirzepatide, survodutide, mazdutide, retatrutide, cagrilintide-semaglutide, and amycretin).”
Beyond weight loss: multisystem benefits of obesity medications. · Abstract
Identity
Retatrutide is described here as a GLP-1 receptor agonist.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy, we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models.”
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. · Abstract
Identity
Retatrutide is an investigational glucagon receptor agonist (GRA)-based agent.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Several investigational GRA-based agents, including retatrutide, cotadutide, mazdutide, and survodutide, have reported promising results across early and mid-phase clinical trials.”
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. · INTRODUCTION
Identity
Retatrutide is described as a latest-generation multi-agonist that incorporates GLP-1.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Tirzepatide and retatrutide, the latest generation of GLP-1-incorporating multi-agonists, target multiple receptors in complementary systems to achieve marked and sustained weight loss.”
Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy? · Abstract
Identity
Retatrutide is a triple agonist for GLP-1, GIP, and glucagon.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Tirzepatide (GLP-1/GIP dual agonist), CagriSema (GLP-1/amylin dual agonist), and retatrutide (GLP-1/GIP/glucagon triple agonist)”
Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. · Abstract
Identity
Retatrutide (LY3437943) is a peptide that agonizes GCGR, GIPR, and GLP-1R.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide (LY3437943) is a triple peptidic agonist of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R)”
IUPHAR ligand commentary · General comments
Identity
Retatrutide is a peptide (IUPHAR Ligand ID 13769; INN: retatrutide).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Name: retatrutide Ligand ID: 13769 Type: Peptide INN: retatrutide”
retatrutide · Identity and approval
Identity
Each kit has retatrutide 10 mg as a lyophilized powder.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide 10 mg (lyophilized powder)”
dailymed-lead-425d04f6 · Active ingredients (in each kit)
Identity
Retatrutide is a peptide that activates three receptors: glucagon, GIP, and GLP-1.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide, a triple agonist peptide targeting the glucagon receptor, GIP receptor, and GLP-1 receptor, shows promise in addressing this need.”
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. · INTRODUCTION
Identity
The inactive ingredient is sterile water for injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Sterile Water for Injection”
dailymed-lead-42498bee · Inactive ingredients
Identity
Retatrutide is an injectable peptide agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide is an injectable peptide agonist of GLP-1R, GIPR, and the glucagon receptor that is undergoing clinical trials for the management of obesity and diabetes.”
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity. · Abstract
Identity
Retatrutide is a novel triple agonist that targets the glucagon receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon-like peptide-1 receptor.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide is a novel triple agonist that targets the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R).”
A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide. · Abstract
Identity
Retatrutide activates GIP, GLP-1, and glucagon receptors.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications.”
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. · BACKGROUND
Identity
Retatrutide is described as a triple agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Dual GIP/GLP-1 agonist tirzepatide and triple agonist retatrutide have shown unprecedented efficacy”
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. · Abstract
Identity
Retatrutide is a triple-receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“GLP‑1/glucagon dual-receptor agonists and triple-receptor agonists (such as retatrutide)”
Synergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy Expenditure. · RECENT FINDINGS
Identity
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist,”
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. · Abstract
Identity
Each kit includes 1 mL of Sterile Water for Injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Sterile Water for Injection 1 mL”
dailymed-lead-425d04f6 · Active ingredients (in each kit)
Identity
Retatrutide was one of the GLP-1-based polyagonists included in the trials reviewed in adults with MASLD or MASH.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The included GLP-1-based polyagonists-tirzepatide, survodutide, pemvidutide, retatrutide, and cotadutide-”
Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis. · Abstract
Identity
Retatrutide is a triple incretin agonist (GIP/GLP-1/glucagon).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Beyond selective GLP-1 receptor agonism, dual (glucose-dependent insulinotropic polypeptide [GIP]/GLP-1) and triple (GIP/GLP-1/glucagon) incretin agonists, including tirzepatide and retatrutide, extend this paradigm”
Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification. · Abstract
Identity
Retatrutide is listed as an “emerging agent” in this network meta-analysis of obesity drugs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Emerging agents (ecnoglutide, mazdutide, retatrutide)”
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. · RESULTS
Identity
Retatrutide is an injectable peptide agonist that activates GLP-1R, GIPR, and the glucagon receptor.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide is an injectable peptide agonist of GLP-1R, GIPR, and the glucagon receptor”
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity. · Abstract
How does it work?
Target, response, and disposition.
Mechanism
The study presents hydrophobic tag-assisted liquid-phase peptide synthesis as a method to make Retatrutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In this study, we present a novel method for the synthesis of Retatrutide, namely hydrophobic tag-assisted liquid-phase peptide synthesis (LPPS).”
A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide. · Abstract
Mechanism
Retatrutide activates GLP-1R, GIPR, and the glucagon receptor.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide is an injectable peptide agonist of GLP-1R, GIPR, and the glucagon receptor that is undergoing clinical trials for the management of obesity and diabetes.”
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity. · Abstract
Mechanism
In phase 2 trials in adults with obesity/overweight (with or without type 2 diabetes), researchers assessed lipoprotein and inflammatory biomarkers post hoc to further characterize retatrutide’s cardiometabolic effects.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D).”
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. · AIMS
Mechanism
In the UUO mouse model, retatrutide was associated with inhibition of both PI3K-AKT and NF-κB pathways.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In the UUO model, semaglutide effects were associated with PI3K-AKT inhibition, tirzepatide effects with PI3K-AKT inhibition and PPAR pathway activation, and retatrutide effects with concurrent inhibition of both PI3K-AKT and NF-κB pathways.”
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. · Abstract
Mechanism
The analysis used mixed models for repeated measures to estimate placebo-adjusted change from baseline.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Mixed models for repeated measures estimated placebo-adjusted change from baseline.”
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. · MATERIALS AND METHODS
Mechanism
Researchers collected fasting blood samples at baseline and during treatment to measure lipids, apolipoproteins, lipoprotein particle subclasses, and inflammatory biomarkers.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Fasting blood samples were collected at baseline and during treatment to assess lipids, apolipoproteins, lipoprotein particle subclasses and inflammatory biomarkers.”
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. · MATERIALS AND METHODS
Mechanism
Retatrutide was studied as a stand-alone treatment in people whose type 2 diabetes was not controlled by diet and exercise alone.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“We aimed to assess the efficacy and safety of retatrutide as a monotherapy in people with type 2 diabetes that is inadequately controlled by diet and exercise alone.”
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. · BACKGROUND
Mechanism
The study tested whether Retatrutide can lessen learning and memory problems in a streptozotocin diabetic rat model.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The present study investigated whether Retatrutide attenuates learning- and memory-related impairments in a streptozotocin-induced, insulin-deficient diabetic rat model.”
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. · Abstract
Mechanism
In vitro, retatrutide activates all three receptors it targets.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide activates all 3 receptors in vitro”
IUPHAR ligand commentary · General comments
Mechanism
The study was a 40-week phase 3 randomized double-blind placebo-controlled trial at 48 sites in the USA, Mexico, and India.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In this 40-week, phase 3, randomised, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico, and India”
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. · METHODS
Mechanism
Retatrutide’s effects on diabetes-related cognitive problems were unclear.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“but its effects on diabetes-associated cognitive dysfunction remain unclear.”
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. · Abstract
Pharmacokinetics
Retatrutide may delay gastric emptying.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide may delay gastric emptying.”
dailymed-lead-425d04f6 · Warnings — Read carefully and tell your doctor if any apply to you.
What has been studied?
What the evidence says.
Comparative evidence
Retatrutide showed the largest weight reduction versus placebo among the agents listed.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide demonstrated the greatest weight reduction versus placebo (MD -13.44 kg; 95% CI [-18.38, -8.51]), followed by survodutide (MD -10.74 kg; 95% CI [-15.68, -5.80]) and mazdutide (MD -6.47 kg; 95% CI [-10.71, -2.24]). Cotadutide showed the smallest and nonsignificant effect (MD -3.41 kg; 95% CI [-11.63, 4.81]).”
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. · RESULTS
Comparative evidence
In the included trials, 510 participants received retatrutide and 130 received placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide was administered to 510 participants, while 130 received a placebo.”
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. · SUMMARY
Comparative evidence
This was a phase 2 randomized, double-blind trial comparing retatrutide with placebo and an active comparator in the USA.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.”
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. · METHODS
Comparative evidence
The review analyzed trials comparing dual or triple GLP-1-based polyagonists to placebo in adults with MASLD or MASH; retatrutide was among the polyagonists.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This systematic review and meta-analysis evaluated randomized controlled trials comparing dual or triple GLP-1-based polyagonists with placebo in adults with MASLD or MASH.”
Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis. · Abstract
Comparative evidence
At 36 weeks, retatrutide at 4 mg or higher led to significantly more weight loss than placebo and dulaglutide.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“For retatrutide doses of 4 mg and greater, decreases in weight were significantly greater than with placebo (p=0·0017 for the 4 mg escalation group and p<0·0001 for others) and 1·5 mg dulaglutide (all p<0·0001).”
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. · FINDINGS
Comparative evidence
Retatrutide lowered HbA1c more than placebo at most doses (not 0·5 mg), and more than dulaglutide at 8 mg slow escalation and 12 mg escalation.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“HbA1creductions with retatrutide were significantly greater (p<0·0001) than placebo in all but the 0·5 mg group and greater than 1·5 mg dulaglutide in the 8 mg slow escalation group (p=0·0019) and 12 mg escalation group (p=0·0002).”
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. · FINDINGS
Study findings
Compared with placebo, retatrutide reduced waist circumference (WMD -6.61 cm; 95 % CI -13.17, -0.05).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“waist circumference (WMD -6.61 cm; 95 % CI -13.17, -0.05)”
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. · RESULTS
Study findings
In adults with overweight or obesity without diabetes, retatrutide was associated with -22.1% placebo-subtracted weight loss (CI, -24.9% to -19.3%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Numerically greater placebo-subtracted reductions were seen with emerging multiagonists, including -23.9% (CI, -29.3% to -18.5%) with amycretin and -22.1% (CI, -24.9% to -19.3%) with retatrutide.”
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review. · DATA SYNTHESIS
Study findings
At week 40, retatrutide lowered HbA1c more than placebo: -0·88% (4 mg), -1·04% (9 mg), and -1·12% (12 mg) vs placebo (all p<0·0001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“For the treatment regimen estimand, the mean change from baseline in HbA1cconcentration was -1·69% (SE 0·11) with retatrutide 4 mg, -1·86% (0·10) with 9 mg, and -1·94% (0·08) with 12 mg, versus -0·81% (0·12) with placebo, resulting in estimated treatment differences versus placebo of -0·88% (95% CI -1·18 to -0·59) with retatrutide 4 mg, -1·04% (-1·32 to -0·76) with 9 mg, and -1·12% (-1·39 to -0·85) with 12 mg (all p<0·0001).”
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. · FINDINGS
Study findings
Retatrutide reduced fasting plasma glucose versus placebo (MD: -23.51 mg/dL; P < 0.00001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide significantly reduced body weight (mean difference [MD]: -14.33%), body mass index (MD: -5.38), waist circumference (MD: -10.51 cm), fasting plasma glucose (MD: -23.51 mg/dL), hemoglobin A1c (MD: -0.91%), and systolic and diastolic blood pressure (MD: -9.88 mm Hg and -3.88 mm Hg, respectively), all withPvalues < 0.00001.”
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. · RESULTS
Study findings
In diabetic rats, Retatrutide lowered blood glucose but did not stop weight loss.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide reduced blood glucose levels but did not prevent diabetes-associated weight loss.”
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. · Abstract
Study findings
In Study 2 (but not Study 1), retatrutide was linked to lower interleukin-6 (-29.6%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide was associated with significant reductions in high-sensitivity C-reactive protein (-54.8%) and interleukin-6 (-29.6%) in Study 2 but not Study 1.”
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. · RESULTS
Study findings
Compared with placebo, retatrutide increased the chance of ≥20% weight loss (RR 16.61; 95% CI 4.17-66.12).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“≥20 % (RR 16.61; 95 % CI 4.17-66.12)”
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. · RESULTS
Study findings
Retatrutide lowered blood glucose in the diabetic rats.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide reduced blood glucose levels”
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. · Abstract
Study findings
In adults with overweight or obesity without diabetes, retatrutide was linked to -22.10% weight loss versus placebo (95% confidence interval -25.60% to -18.60%) in this network meta-analysis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Compared with placebo, weight loss was greatest with retatrutide (-22.10%, 95% confidence interval -25.60% to -18.60%),”
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. · RESULTS
Study findings
At 24 weeks, 12 mg retatrutide had -17.5% weight change versus -1.6% with placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group.”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. · Abstract
Study findings
Adverse events did not differ significantly between retatrutide and placebo (relative risk: 1.11; P= 0.24).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“No significant difference in adverse events was observed between the groups (relative risk: 1.11,P= 0.24).”
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. · RESULTS
Study findings
Retatrutide reduced waist circumference versus placebo (MD: -10.51 cm; P < 0.00001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide significantly reduced body weight (mean difference [MD]: -14.33%), body mass index (MD: -5.38), waist circumference (MD: -10.51 cm), fasting plasma glucose (MD: -23.51 mg/dL), hemoglobin A1c (MD: -0.91%), and systolic and diastolic blood pressure (MD: -9.88 mm Hg and -3.88 mm Hg, respectively), all withPvalues < 0.00001.”
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. · RESULTS
Study findings
Compared with placebo, retatrutide increased the chance of ≥10% weight loss (RR 9.32; 95% CI 4.56-19.06).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“≥10 % (RR 9.32; 95 % CI 4.56-19.06)”
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. · RESULTS
Study findings
The review included three articles; 1,082 patients were screened and 691 were randomized.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Three articles were included in this systematic review, screening a total of 1,082 patients, with 691 randomly assigned to groups.”
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. · SUMMARY
Study findings
Compared with placebo, retatrutide reduced BMI (WMD -4.53 kg/m2; 95 % CI -7.51, -1.55).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“body mass index (WMD -4.53 kg/m2; 95 % CI -7.51, -1.55)”
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. · RESULTS
Study findings
Retatrutide was tested for anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis in HK-2 cells and mouse UUO and aging models.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models.”
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. · Abstract
Study findings
At 36 weeks, bodyweight dropped more as retatrutide dose increased (up to 16·94%), compared with 3·00% with placebo and 2·02% with dulaglutide.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Bodyweight decreased dose dependently with retatrutide at 36 weeks by 3·19% (SE 0·61) for the 0·5 mg group, 7·92% (1·28) for the 4 mg escalation group, 10·37% (1·56) for the 4 mg group, 16·81% (1·59) for the 8 mg slow escalation group, 16·34% (1·65) for the 8 mg fast escalation group, and 16·94% (1·30) for the 12 mg escalation group, versus 3·00% (0·86) with placebo and 2·02% (0·72) with 1·5 mg dulaglutide.”
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. · FINDINGS
Study findings
Retatrutide reduced body weight versus placebo (MD: -14.33%; P < 0.00001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide significantly reduced body weight (mean difference [MD]: -14.33%), body mass index (MD: -5.38), waist circumference (MD: -10.51 cm), fasting plasma glucose (MD: -23.51 mg/dL), hemoglobin A1c (MD: -0.91%), and systolic and diastolic blood pressure (MD: -9.88 mm Hg and -3.88 mm Hg, respectively), all withPvalues < 0.00001.”
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. · RESULTS
Study findings
The main outcome was HbA1c change at 24 weeks; secondary outcomes included HbA1c and weight change at 36 weeks.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The primary endpoint was change in HbA1cfrom baseline to 24 weeks, and secondary endpoints included change in HbA1cand bodyweight at 36 weeks.”
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. · METHODS
Study findings
Retatrutide did not stop the diabetes-related weight loss.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“but did not prevent diabetes-associated weight loss.”
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. · Abstract
Study findings
At 48 weeks, 1 mg retatrutide had -8.7% weight change versus -2.1% with placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group.”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. · Abstract
Study findings
Retatrutide reduced weight more than placebo (MD -13.44 kg; 95% CI [-18.38, -8.51]).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide demonstrated the greatest weight reduction versus placebo (MD -13.44 kg; 95% CI [-18.38, -8.51])”
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. · RESULTS
Study findings
At 24 weeks, 1 mg retatrutide once weekly reduced body weight by -7.2% (least-squares mean) versus -1.6% with placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group.”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. · Abstract
Study findings
In Study 2 (but not Study 1), retatrutide was linked to lower high-sensitivity C-reactive protein (-54.8%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide was associated with significant reductions in high-sensitivity C-reactive protein (-54.8%) and interleukin-6 (-29.6%) in Study 2 but not Study 1.”
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. · RESULTS
Study findings
Retatrutide reduced BMI versus placebo (MD: -5.38; P < 0.00001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide significantly reduced body weight (mean difference [MD]: -14.33%), body mass index (MD: -5.38), waist circumference (MD: -10.51 cm), fasting plasma glucose (MD: -23.51 mg/dL), hemoglobin A1c (MD: -0.91%), and systolic and diastolic blood pressure (MD: -9.88 mm Hg and -3.88 mm Hg, respectively), all withPvalues < 0.00001.”
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. · RESULTS
Study findings
At 48 weeks, 12 mg retatrutide had -24.2% weight change versus -2.1% with placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group.”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. · Abstract
Study findings
In two phase 2 studies of adults with obesity/overweight, retatrutide was linked to lower non-HDL cholesterol (up to -21.0% in Study 1 and up to -26.9% in Study 2).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In both studies, retatrutide was associated with significant reductions in non-high-density lipoprotein cholesterol (Study 1: up to -21.0%, Study 2: up to -26.9%)”
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. · RESULTS
Study findings
Retatrutide was tested for anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis in HK-2 cells and mouse UUO and aging models.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy, we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models.”
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. · Abstract
Studied populations
It has not been studied in patients with severe GI disorders; use is not recommended.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Severe gastrointestinal disease: RETATRUTIDE has not been studied in patients with severe GI disorders; use is not recommended.”
dailymed-lead-42498bee · Warnings
Risks and interactions
Risks, organized for scanning.
Contraindications
Do not use retatrutide if you have a history of recurrent or severe hypoglycemia.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia.”
dailymed-lead-42498bee · Warnings
- supports · Source-backed record
“Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia.”
dailymed-lead-425d04f6 · Warnings — Read carefully and tell your doctor if any apply to you.
Contraindications
Do not use it if you have a history of recurrent or severe hypoglycemia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia.”
dailymed-lead-42498bee · Warnings
Contraindications
Do not use retatrutide if you are pregnant or breastfeeding.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Pregnancy and breastfeeding: Do not use if pregnant or breastfeeding.”
dailymed-lead-42498bee · Warnings
Interactions
Using it with insulin or sulfonylureas may increase hypoglycemia risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Using it with insulin or sulfonylureas may increase the risk of hypoglycemia.”
dailymed-lead-42498bee · Warnings
Safety findings
Acute pancreatitis has been reported with GLP-1 receptor agonists.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Pancreatitis: Acute pancreatitis has been reported with GLP-1 receptor agonists.”
dailymed-lead-42498bee · Warnings
Safety findings
Serious allergic reactions, including anaphylaxis, have been reported.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Allergic reactions: Serious hypersensitivity reactions (including anaphylaxis) have been reported.”
dailymed-lead-42498bee · Warnings
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
Dose records
From week 13 and beyond: 0.75 mL (10 mg) once weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Week 13 and beyond 0.75 mL (10 mg) once weekly”
dailymed-lead-42498bee · Titration schedule:
Dose records
Each kit has Retatrutide 10 mg (lyophilized powder) and Sterile Water for Injection 1 mL.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide 10 mg (lyophilized powder)Sterile Water for Injection 1 mL”
dailymed-lead-425d04f6 · Active ingredients (in each kit)
Dose records
For weeks 1–4, the dose is 0.19 mL (2.5 mg) once weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Weeks 1–4 0.19 mL (2.5 mg) once weekly”
dailymed-lead-42498bee · Titration schedule:
Dose records
After reconstitution, the concentration is 10 mg/mL.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“10 mg ÷ 1 mL = 10 mg/mL.”
dailymed-lead-425d04f6 · Directions — Preparation & Dosing (basic patient summary)
Additional research & classification gaps
5 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (5)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Retatrutide is currently made mostly using solid-phase peptide synthesis, which has limitations in efficiency, scalability, and structural flexibility.
Research context only—not evidence of a treatment effect.
- A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide.
At present, its synthesis relies predominantly on solid-phase peptide synthesis (SPPS), an approach that suffers from inherent limitations in terms of efficiency, scalability, and structural flexibility.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Hydrophobic tag-assisted LPPS is presented as a practical and flexible alternative to conventional SPPS for making Retatrutide.
Research context only—not evidence of a treatment effect.
- A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide.
This method provides a practical and flexible alternative to conventional SPPS for the synthesis of Retatrutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The preferred name is RETATRUTIDE.
Research context only—not evidence of a treatment effect.
- RETATRUTIDE
Preferred name: RETATRUTIDE
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Retatrutide’s ChEMBL ID is CHEMBL5095485.
Research context only—not evidence of a treatment effect.
- RETATRUTIDE
ChEMBL ID: CHEMBL5095485
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Retatrutide is also known as LY-3437943 and LY3437943.
Research context only—not evidence of a treatment effect.
- RETATRUTIDE
LY-3437943; LY3437943; Retatrutide
Research status + gaps
What still needs better answers?
- Not yet covered in this profile: administration, regulatory status.
- Some extracted findings are not shown because they did not pass Peplexicon's automated evidence checks.
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- RETATRUTIDE ↗
chembl-molecule · published August 29, 2026 · retrieved August 29, 2026
- dailymed-lead-42498bee ↗
dailymed · published October 29, 2025 · retrieved September 4, 2026
- dailymed-lead-425d04f6 ↗
dailymed · published October 30, 2025 · retrieved September 4, 2026
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗
doi · published June 26, 2023 · retrieved September 4, 2026
- IUPHAR ligand commentary ↗
iuphar-comments · published August 29, 2026 · retrieved August 29, 2026
- retatrutide ↗
iuphar-ligand · published August 29, 2026 · retrieved August 29, 2026
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. ↗
pubmed · published August 12, 2023 · retrieved September 4, 2026
- Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. ↗
pubmed · published December 1, 2024 · retrieved September 9, 2026
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. ↗
pubmed · published January 1, 2025 · retrieved September 9, 2026
- Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. ↗
pubmed · published July 1, 2025 · retrieved September 9, 2026
- Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. ↗
pubmed · published April 1, 2026 · retrieved September 2, 2026
- Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. ↗
pubmed · published March 1, 2026 · retrieved September 6, 2026
- Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. ↗
pubmed · published April 1, 2026 · retrieved August 26, 2026
- Beyond weight loss: multisystem benefits of obesity medications. ↗
pubmed · published August 1, 2026 · retrieved August 21, 2026
- A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide. ↗
pubmed · published June 12, 2026 · retrieved September 6, 2026
- Synergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy Expenditure. ↗
pubmed · published June 6, 2026 · retrieved September 6, 2026
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. ↗
pubmed · published June 13, 2026 · retrieved September 4, 2026
- Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. ↗
pubmed · published October 2, 2026 · retrieved August 29, 2026
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. ↗
pubmed · published July 8, 2026 · retrieved August 24, 2026
- Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis. ↗
pubmed · published June 1, 2026 · retrieved August 29, 2026
- The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity. ↗
pubmed · published September 1, 2026 · retrieved August 27, 2026
- Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy? ↗
pubmed · published January 1, 2026 · retrieved August 21, 2026
- Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. ↗
pubmed · published August 17, 2026 · retrieved August 29, 2026
- Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. ↗
pubmed · published September 18, 2026 · retrieved August 25, 2026
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review. ↗
pubmed · published September 1, 2026 · retrieved September 1, 2026
- Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification. ↗
pubmed · published September 1, 2026 · retrieved September 3, 2026
- Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. ↗
pubmed · published January 1, 2026 · retrieved September 5, 2026
Publication history and provenance
Version 19 · Automated assessment · September 12, 2026
91485b50c98035fff5c95596ad5459d4c8fddec4e3d3dd410351074bac59fcd1